Article Text

other Versions

PDF
Rhodococcus equi hyperimmune plasma decreases pneumonia severity after a randomised experimental challenge of neonatal foals
  1. M. G. Sanz, DVM, MS, DACVIM, PhD1,
  2. A. Loynachan, DVM, DACVP, PhD2 and
  3. D. W. Horohov, PhD1
  1. 1Maxwell H. Gluck Equine Research Center, University of Kentucky, Lexington, KY, 40546-0099, USA
  2. 2Veterinary Diagnostic Laboratory, Department of Veterinary Science, University of Kentucky, Lexington, KY, 40546-0099, USA
  1. Correspondence to E-mail for correspondence: dwhoro2{at}uky.edu

Abstract

Since a vaccine is not available against Rhodococcus equi, R equi-specific hyperimmune plasma (HIP) is commonly used, although its efficacy remains controversial. The objective of this study was to evaluate the ability of a commercially available HIP to prevent clinical rhodococcal pneumonia in neonatal foals after experimental challenge.

  • Respiratory disease
  • Horses
  • Bacterial diseases
  • Accepted February 7, 2016.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.